Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

M. O'Brien, J. Jassem, P. Lorigan, L. Bosquée, E. Marshall, F. Bustin, J. Stigt, A. C. Dingemans, B. Hasan, J. P. Van Meerbeeck

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)7052-7052
    Number of pages1
    JournalJournal of Clinical Oncology
    Issue number15_suppl
    Publication statusPublished - 24 Feb 2017

    Research Beacons, Institutes and Platforms

    • Manchester Cancer Research Centre

    Cite this